HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
Key Highlights
- ➤EXIT-CVD consortium includes 42 partners across 17 countries and 22 studies.
- ➤HEART-CHECK will evaluate HeartBeam’s 3D ECG for post-ACS event detection.
- ➤EXIT-CVD involves more than 14,000 patients and a EUR 27.6 million budget.
- ➤FDA granted Breakthrough Device Designation for HeartBeam’s at-home heart-attack assessment tool.
- ➤HeartBeam’s contribution is in-kind, including devices and clinical team expertise.
Expert Statements
Branislav Vajdic, Founder and President of HeartBeam
“Patients discharged after an ACS are in a vulnerable period, and their symptoms can be atypical and easily dismissed.”
Branislav Vajdic, Founder and President of HeartBeam
“HEART-CHECK gives us the opportunity to evaluate whether a clinical-grade ECG recording outside of a medical facility can help clinicians recognize recurrent events earlier and get these patients to the right care sooner.”
Branislav Vajdic, Founder and President of HeartBeam
“Our priority remains FDA clearance for heart attack assessment.”
Branislav Vajdic, Founder and President of HeartBeam
“HEART-CHECK builds on our heart attack detection work, as we continue to advance opportunities for heart attack assessment outside of the healthcare facility.”
Branislav Vajdic, Founder and President of HeartBeam
“Being invited to contribute alongside some of the world’s leading cardiovascular institutions and companies affirms the importance of acting at the right point along the cardiac care journey.”
Pim van der Harst, Project Coordinator of EXIT-CVD and Head of Cardiology at the University Medical Center Groningen
“Our vision is a future where heart disease is no longer an irreversible pathway.”
Pim van der Harst, Project Coordinator of EXIT-CVD and Head of Cardiology at the University Medical Center Groningen
“By understanding both the biological and social drivers of cardiovascular disease, and deploying integrated innovations across diagnostics, monitoring, and care, we can empower patients and clinicians to exit the disease continuum before it’s too late.”
Robin Nijveldt, Chief of Cardiology at UMC Utrecht
“For more than 30 years, we have viewed cardiovascular disease as a continuous journey, from risk factors such as hypertension, to atherosclerosis, a first cardiac event and ultimately, for many patients, heart failure.”
Robin Nijveldt, Chief of Cardiology at UMC Utrecht
“Yet most of us improve care within our own specialty and rarely have a complete view of the patient’s experience.”
Robin Nijveldt, Chief of Cardiology at UMC Utrecht
“EXIT-CVD is an ambitious effort to build that holistic view together, helping transform cardiac care for millions of patients across Europe.”
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
* HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium
Get started
Create a free account to read the full story.